{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:13:41Z","timestamp":1792815221145,"version":"4.5.0"},"reference-count":182,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.blre.2023.101055","type":"journal-article","created":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T16:12:22Z","timestamp":1676391142000},"page":"101055","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["TP53 in AML and MDS: The new (old) kid on the block"],"prefix":"10.1016","volume":"60","author":[{"given":"Jennifer A.","family":"Marks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena M.","family":"Fenu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Bagg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.blre.2023.101055_bb0005","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.blre.2023.101055_bb0010","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/nrc.2016.112","article-title":"The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia","volume":"17","author":"Sperling","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"10.1016\/j.blre.2023.101055_bb0015","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/gcc.21993","article-title":"Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion","volume":"51","author":"Sebaa","year":"2012","journal-title":"Genes Chromosomes Cancer"},{"issue":"10","key":"10.1016\/j.blre.2023.101055_bb0020","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1182\/blood-2018-10-844621","article-title":"Genetics of MDS","volume":"133","author":"Ogawa","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2023.101055_bb0025","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1182\/asheducation-2016.1.348","article-title":"Mutations in AML: prognostic and therapeutic implications","volume":"2016","author":"DiNardo","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"6","key":"10.1016\/j.blre.2023.101055_bb0030","doi-asserted-by":"crossref","first-page":"956","DOI":"10.3324\/haematol.2013.085217","article-title":"Clinical and genetic predictors of prognosis in myelodysplastic syndromes","volume":"99","author":"Bejar","year":"2014","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.blre.2023.101055_bb0035","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a001008","article-title":"TP53 mutations in human cancers: origins, consequences, and clinical use","volume":"2","author":"Olivier","year":"2010","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.blre.2023.101055_bb0040","first-page":"OF1","article-title":"TP53-mutated myelodysplastic syndrome and acute myeloid leukemia: biology, current therapy, and future directions","author":"Daver","year":"2022","journal-title":"Cancer Discov"},{"issue":"10","key":"10.1016\/j.blre.2023.101055_bb0045","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nrc1455","article-title":"Post-translational modification of p53 in tumorigenesis","volume":"4","author":"Bode","year":"2004","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.blre.2023.101055_bb0050","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrclinonc.2017.151","article-title":"Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others","volume":"15","author":"Sabapathy","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"6810","key":"10.1016\/j.blre.2023.101055_bb0055","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/35042675","article-title":"Surfing the p53 network","volume":"408","author":"Vogelstein","year":"2000","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.blre.2023.101055_bb0060","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1080\/10428194.2016.1266625","article-title":"The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications","volume":"58","author":"Zhang","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.blre.2023.101055_bb0065","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1182\/bloodadvances.2019001101","article-title":"Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes","volume":"4","author":"Montalban-Bravo","year":"2020","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.blre.2023.101055_bb0070","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","article-title":"Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes","volume":"26","author":"Bernard","year":"2020","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.blre.2023.101055_bb0075","doi-asserted-by":"crossref","first-page":"908","DOI":"10.3324\/haematol.2012.076729","article-title":"Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia","volume":"98","author":"Shih","year":"2013","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.blre.2023.101055_bb0080","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1200\/JCO.2001.19.5.1405","article-title":"Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis","volume":"19","author":"Christiansen","year":"2001","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.blre.2023.101055_bb0085","doi-asserted-by":"crossref","first-page":"4296","DOI":"10.1182\/blood.V88.11.4296.bloodjournal88114296","article-title":"Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype","volume":"88","author":"Ben-Yehuda","year":"1996","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2023.101055_bb0090","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/ejh.13207","article-title":"Molecular pathogenesis of myelodysplastic syndromes with deletion 5q","volume":"102","author":"Lee","year":"2019","journal-title":"Eur J Haematol"},{"issue":"10","key":"10.1016\/j.blre.2023.101055_bb0095","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21103432","article-title":"TP53 in myelodysplastic syndromes: recent biological and clinical findings","volume":"21","author":"Cumbo","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.blre.2023.101055_bb0100","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/bjh.12203","article-title":"TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis","volume":"160","author":"Kulasekararaj","year":"2013","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.blre.2023.101055_bb0105","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1038\/s41375-018-0351-2","article-title":"TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups","volume":"33","author":"Haase","year":"2019","journal-title":"Leukemia"},{"issue":"53","key":"10.1016\/j.blre.2023.101055_bb0110","doi-asserted-by":"crossref","first-page":"7644","DOI":"10.1038\/sj.onc.1203015","article-title":"Regulation of p53 in response to DNA damage","volume":"18","author":"Lakin","year":"1999","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.blre.2023.101055_bb0115","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a000919","article-title":"The tumor suppressor p53: from structures to drug discovery","volume":"2","author":"Joerger","year":"2010","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"3","key":"10.1016\/j.blre.2023.101055_bb0120","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/leu.2016.263","article-title":"The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases","volume":"31","author":"Stengel","year":"2017","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.blre.2023.101055_bb0125","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1002\/ajh.25255","article-title":"P53 protein overexpression in de novo acute myeloid leukemia patients with normal diploid karyotype correlates with FLT3 internal tandem duplication and worse relapse-free survival","volume":"93","author":"Assi","year":"2018","journal-title":"Am J Hematol"},{"issue":"15","key":"10.1016\/j.blre.2023.101055_bb0130","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood.2021014472","article-title":"Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"139","author":"Grob","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2023.101055_bb0135","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/leu.2015.304","article-title":"Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes","volume":"30","author":"Sallman","year":"2016","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/j.blre.2023.101055_bb0140","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13215392","article-title":"TP53 in myelodysplastic syndromes","volume":"13","author":"Jiang","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"22","key":"10.1016\/j.blre.2023.101055_bb0145","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1002\/cncr.30203","article-title":"TP53 mutations in newly diagnosed acute myeloid leukemia: clinicomolecular characteristics, response to therapy, and outcomes","volume":"122","author":"Kadia","year":"2016","journal-title":"Cancer"},{"issue":"7540","key":"10.1016\/j.blre.2023.101055_bb0150","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nature13968","article-title":"Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia","volume":"518","author":"Wong","year":"2015","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.blre.2023.101055_bb0155","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.blre.2023.101055_bb0160","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemia: integrating morphological, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.blre.2023.101055_bb0165","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41568-020-0262-1","article-title":"p53: 800 million years of evolution and 40 years of discovery","volume":"20","author":"Levine","year":"2020","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"10.1016\/j.blre.2023.101055_bb0170","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/s41388-021-02141-5","article-title":"p53 partial loss-of-function mutations sensitize to chemotherapy","volume":"41","author":"Klimovich","year":"2022","journal-title":"Oncogene"},{"issue":"11","key":"10.1016\/j.blre.2023.101055_bb0175","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1016\/j.celrep.2019.08.061","article-title":"Integrated analysis of TP53 gene and pathway alterations in the cancer genome atlas","volume":"28","author":"Donehower","year":"2019","journal-title":"Cell Rep"},{"issue":"3","key":"10.1016\/j.blre.2023.101055_bb0180","doi-asserted-by":"crossref","first-page":"516","DOI":"10.3324\/haematol.2018.205013","article-title":"Clinical implications of subclonal TP53 mutations in acute myeloid leukemia","volume":"104","author":"Prochazka","year":"2019","journal-title":"Haematologica"},{"issue":"15","key":"10.1016\/j.blre.2023.101055_bb0185","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1038\/sj.onc.1210302","article-title":"TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes","volume":"26","author":"Petitjean","year":"2007","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.blre.2023.101055_bb0190","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ccr.2014.01.021","article-title":"Mutant p53 in cancer: new functions and therapeutic opportunities","volume":"25","author":"Muller","year":"2014","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.blre.2023.101055_bb0195","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41418-018-0126-3","article-title":"TP53 gain-of-function mutation promotes inflammation in glioblastoma","volume":"26","author":"Ham","year":"2019","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.blre.2023.101055_bb0200","first-page":"57","article-title":"Uncovering the role of p53 splice variants in human malignancy: a clinical perspective","volume":"7","author":"Surget","year":"2014","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.blre.2023.101055_bb0205","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3389\/fmolb.2018.00080","article-title":"The cancer spliceome: reprograming of alternative splicing in cancer","volume":"5","author":"El Marabti","year":"2018","journal-title":"Front Mol Biosci"},{"issue":"6453","key":"10.1016\/j.blre.2023.101055_bb0210","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1126\/science.aax3649","article-title":"A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies","volume":"365","author":"Boettcher","year":"2019","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.blre.2023.101055_bb0215","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1177\/1947601911408889","article-title":"Mutations in the p53 tumor suppressor gene: important milestones at the various steps of tumorigenesis","volume":"2","author":"Rivlin","year":"2011","journal-title":"Genes Cancer"},{"key":"10.1016\/j.blre.2023.101055_bb0220","article-title":"TP53 mutations in acute myeloid leukemia: still a daunting challenge?","volume":"10","author":"Molica","year":"2020","journal-title":"Front Oncol"},{"issue":"12","key":"10.1016\/j.blre.2023.101055_bb0225","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 ELN recommendations from an international expert panel","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.blre.2023.101055_bb0230","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2023.101055_bb0235","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1038\/s41375-022-01561-w","article-title":"The complex karyotype in hematological malignancies: a comprehensive overview by the Francophone Group of Hematological Cytogenetics (GFCH)","volume":"36","author":"Nguyen-Khac","year":"2022","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.blre.2023.101055_bb0240","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/sj.leu.2403187","article-title":"Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML","volume":"18","author":"Schoch","year":"2004","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.blre.2023.101055_bb0245","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/s41375-020-0917-7","article-title":"Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS","volume":"35","author":"Kuendgen","year":"2021","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.blre.2023.101055_bb0250","first-page":"2454","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood J Am Soc Hematol."},{"issue":"9","key":"10.1016\/j.blre.2023.101055_bb0255","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1182\/bloodadvances.2021006239","article-title":"TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS\/AML","volume":"6","author":"Weinberg","year":"2022","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.blre.2023.101055_bb0260","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1182\/blood-2011-08-375758","article-title":"TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome","volume":"119","author":"Rucker","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2023.101055_bb0265","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1053\/j.seminoncol.2011.04.010","article-title":"Molecular dissection of the 5q deletion in myelodysplastic syndrome","volume":"38","author":"Ebert","year":"2011","journal-title":"Semin Oncol"},{"issue":"11","key":"10.1016\/j.blre.2023.101055_bb0270","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1200\/JCO.20.01659","article-title":"Classification and personalized prognostic assessment on the basis of clinical and genomic features in myelodysplastic syndromes","volume":"39","author":"Bersanelli","year":"2021","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101055_bb0275","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1182\/blood-2018-99-114151","article-title":"Chromothripsis in high-risk myelodysplastic syndromes: incidence, genetic features, clinical implications, and impact on survival of patients treated with azacytidine (data from Czech MDS Group)","volume":"132","author":"Zemanova","year":"2018","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.blre.2023.101055_bb0280","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221810105","article-title":"Personalized medicine for TP53 mutated myelodysplastic syndromes and acute myeloid leukemia","volume":"22","author":"Cluzeau","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10.1016\/j.blre.2023.101055_bb0285","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/ajh.25486","article-title":"DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease","volume":"94","author":"Quesada","year":"2019","journal-title":"Am J Hematol"},{"issue":"22","key":"10.1016\/j.blre.2023.101055_bb0290","first-page":"6094","article-title":"Follow-up study of twenty-four families with Li-Fraumeni syndrome","volume":"51","author":"Garber","year":"1991","journal-title":"Cancer Res"},{"issue":"34","key":"10.1016\/j.blre.2023.101055_bb0295","doi-asserted-by":"crossref","first-page":"5358","DOI":"10.1200\/JCO.2006.07.5598","article-title":"Myelodysplastic syndromes in patients younger than age 50","volume":"24","author":"Kuendgen","year":"2006","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.blre.2023.101055_bb0300","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.blre.2023.101055_bb0305","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3109\/10428194.2015.1115041","article-title":"Genetic predisposition to myelodysplastic syndrome and acute myeloid leukemia in children and young adults","volume":"57","author":"Babushok","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.blre.2023.101055_bb0310","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s41568-020-00315-z","article-title":"Advances in germline predisposition to acute leukaemias and myeloid neoplasms","volume":"21","author":"Klco","year":"2021","journal-title":"Nat Rev Cancer"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101055_bb0315","first-page":"4231","article-title":"Presence of rare germline variants in Fanconi anaemia pathway genes confers a poor prognosis comparable to TP53 mutations in therapy-related myeloid neoplasms","volume":"130","author":"Singhal","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2023.101055_bb0320","doi-asserted-by":"crossref","DOI":"10.1101\/mcs.a003210","article-title":"Hematologic malignancies and Li-Fraumeni syndrome","volume":"5","author":"Swaminathan","year":"2019","journal-title":"Cold Spring Harb Mol Case Stud"},{"issue":"1","key":"10.1016\/j.blre.2023.101055_bb0325","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S1470-2045(16)30627-1","article-title":"Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study","volume":"18","author":"Gillis","year":"2017","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.blre.2023.101055_bb0330","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1521-6616(03)00207-9","article-title":"Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS","volume":"109","author":"Leone","year":"2003","journal-title":"Clin Immunol"},{"issue":"5","key":"10.1016\/j.blre.2023.101055_bb0335","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/ejh.13483","article-title":"The prognostic impact of variant allele frequency (VAF) in TP53 mutant patients with MDS: a systematic review and meta-analysis","volume":"105","author":"Deng","year":"2020","journal-title":"Eur J Haematol"},{"issue":"8","key":"10.1016\/j.blre.2023.101055_bb0340","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1038\/leu.2016.74","article-title":"High prevalence and allele burden-independent prognostic importance of p53 mutations in an inner-city MDS\/AML cohort","volume":"30","author":"Goel","year":"2016","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.blre.2023.101055_bb0345","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2023.101055_bb0350","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/s41375-022-01766-z","article-title":"Prognostic implications of mono-hit and multi-hit TP53 alterations in patients with acute myeloid leukemia and higher risk myelodysplastic syndromes treated with azacitidine-based therapy","volume":"37","author":"Zeidan","year":"2023","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.blre.2023.101055_bb0355","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.leukres.2014.03.012","article-title":"Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine","volume":"38","author":"Bally","year":"2014","journal-title":"Leuk Res"},{"issue":"7176","key":"10.1016\/j.blre.2023.101055_bb0360","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nature06494","article-title":"Identification of RPS14 as a 5q- syndrome gene by RNA interference screen","volume":"451","author":"Ebert","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.blre.2023.101055_bb0365","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev.pharmtox.48.113006.094723","article-title":"Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy","volume":"49","author":"Shangary","year":"2009","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"7","key":"10.1016\/j.blre.2023.101055_bb0370","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/sj.onc.1210707","article-title":"HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function","volume":"27","author":"Lau","year":"2008","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.blre.2023.101055_bb0375","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular international prognostic scoring system for myelodysplastic syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evidence"},{"key":"10.1016\/j.blre.2023.101055_bb0380","author":"Byrne"},{"issue":"1","key":"10.1016\/j.blre.2023.101055_bb0385","doi-asserted-by":"crossref","first-page":"389","DOI":"10.4081\/oncol.2019.389","article-title":"Complex karyotype in myelodysplastic syndromes: diagnostic procedure and prognostic susceptibility","volume":"13","author":"Shahjahani","year":"2019","journal-title":"Oncol Rev"},{"issue":"15","key":"10.1016\/j.blre.2023.101055_bb0390","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1182\/blood.2021014309","article-title":"Guiding the global evolution of cytogenetic testing for hematologic malignancies","volume":"139","author":"Akkari","year":"2022","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.blre.2023.101055_bb0395","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1182\/blood.2022015853","article-title":"Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia","volume":"140","author":"Duncavage","year":"2022","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2023.101055_bb0400","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1093\/ajcp\/aqy076","article-title":"The utilization of chromosomal microarray technologies for hematologic neoplasms: an ACLPS critical review","volume":"150","author":"Peterson","year":"2018","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"10.1016\/j.blre.2023.101055_bb0405","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.htct.2020.05.005","article-title":"Detection of somatic TP53 mutations and 17p deletions in patients with chronic lymphocytic leukemia: a review of the current methods","volume":"42","author":"Chauffaille","year":"2020","journal-title":"Hematol Transfus Cell Ther"},{"issue":"2","key":"10.1016\/j.blre.2023.101055_bb0410","doi-asserted-by":"crossref","first-page":"106","DOI":"10.6004\/jnccn.2022.0009","article-title":"NCCN guidelines(R) insights: myelodysplastic syndromes, version 3.2022","volume":"20","author":"Greenberg","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"26","key":"10.1016\/j.blre.2023.101055_bb0415","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.blre.2023.101055_bb0420","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41408-018-0148-6","article-title":"Challenges in the introduction of next-generation sequencing (NGS) for diagnostics of myeloid malignancies into clinical routine use","volume":"8","author":"Bacher","year":"2018","journal-title":"Blood Cancer J"},{"issue":"19","key":"10.1016\/j.blre.2023.101055_bb0425","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1158\/0008-5472.CAN-22-0172","article-title":"Benign SNPs in the coding region of TP53: finding the needles in a haystack of pathogenic variants","volume":"82","author":"Soussi","year":"2022","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.blre.2023.101055_bb0430","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/s41375-017-0007-7","article-title":"ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation","volume":"32","author":"Malcikova","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.blre.2023.101055_bb0435","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12863-020-00956-x","article-title":"A simple method to estimate the in-house limit of detection for genetic mutations with low allele frequencies in whole-exome sequencing analysis by next-generation sequencing","volume":"22","author":"Miura","year":"2021","journal-title":"BMC Genom Data"},{"issue":"21","key":"10.1016\/j.blre.2023.101055_bb0440","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1182\/blood.V124.21.3266.3266","article-title":"Detection of TP53 mutations in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). A comparison between a functional method (FASAY) and next generation sequencing (NGS)","volume":"124","author":"Bally","year":"2014","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.blre.2023.101055_bb0445","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1073\/pnas.082100599","article-title":"Evaluating the arrayed primer extension resequencing assay of TP53 tumor suppressor gene","volume":"99","author":"Tonisson","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.blre.2023.101055_bb0450","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1007\/s13277-014-2971-0","article-title":"TP53 mutation analysis in chronic lymphocytic leukemia: comparison of different detection methods","volume":"36","author":"Kantorova","year":"2015","journal-title":"Tumour Biol"},{"issue":"4","key":"10.1016\/j.blre.2023.101055_bb0455","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/leu.2014.297","article-title":"Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia","volume":"29","author":"Malcikova","year":"2015","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.blre.2023.101055_bb0460","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2144\/000112000","article-title":"Evaluation of arrayed primer extension for TP53 mutation detection in breast and ovarian carcinomas","volume":"39","author":"Kringen","year":"2005","journal-title":"Biotechniques"},{"issue":"4","key":"10.1016\/j.blre.2023.101055_bb0465","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/leu.2008.375","article-title":"The prognostic impact of 17p (p53) deletion in 2272 adults with acute myeloid leukemia","volume":"23","author":"Seifert","year":"2009","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.blre.2023.101055_bb0470","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/sj.leu.2401298","article-title":"Therapy-related myelodysplastic syndrome and acute myeloid leukemia with 17p deletion. A report on 25 cases","volume":"13","author":"Merlat","year":"1999","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.blre.2023.101055_bb0475","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.leukres.2013.04.010","article-title":"Characterization and prognostic implication of 17 chromosome abnormalities in myelodysplastic syndrome","volume":"37","author":"Sanchez-Castro","year":"2013","journal-title":"Leuk Res"},{"issue":"11","key":"10.1016\/j.blre.2023.101055_bb0480","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.3109\/10428194.2015.1028053","article-title":"Fluorescence in situ hybridization of TP53 for the detection of chromosome 17 abnormalities in myelodysplastic syndromes","volume":"56","author":"Sanchez-Castro","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"17","key":"10.1016\/j.blre.2023.101055_bb0485","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1182\/blood-2013-03-492884","article-title":"Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet","volume":"122","author":"Malcovati","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2023.101055_bb0490","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1038\/s41598-021-81467-2","article-title":"Genomic variations in patients with myelodysplastic syndrome and karyotypes without numerical or structural changes","volume":"11","author":"Ribeiro","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.blre.2023.101055_bb0495","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.critrevonc.2019.07.016","article-title":"Clinical use of SNP-microarrays for the detection of genome-wide changes in haematological malignancies","volume":"142","author":"Berry","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"issue":"12","key":"10.1016\/j.blre.2023.101055_bb0500","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1002\/gcc.22112","article-title":"Single nucleotide polymorphism array karyotyping: a diagnostic and prognostic tool in myelodysplastic syndromes with unsuccessful conventional cytogenetic testing","volume":"52","author":"Arenillas","year":"2013","journal-title":"Genes Chromosomes Cancer"},{"issue":"9","key":"10.1016\/j.blre.2023.101055_bb0505","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1038\/s41375-022-01652-8","article-title":"High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance","volume":"36","author":"Yang","year":"2022","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.blre.2023.101055_bb0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2020.153025","article-title":"Diagnostic accuracy of p53 immunohistochemistry as surrogate of TP53 sequencing in endometrial cancer","volume":"216","author":"Raffone","year":"2020","journal-title":"Pathol Res Pract"},{"issue":"1","key":"10.1016\/j.blre.2023.101055_bb0515","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/his.14109","article-title":"Performance of the pattern-based interpretation of p53 immunohistochemistry as a surrogate for TP53 mutations in vulvar squamous cell carcinoma","volume":"77","author":"Kortekaas","year":"2020","journal-title":"Histopathology"},{"key":"10.1016\/j.blre.2023.101055_bb0520","doi-asserted-by":"crossref","first-page":"4967","DOI":"10.2147\/OTT.S321949","article-title":"TP53 co-mutational features and NGS-calibrated immunohistochemistry threshold in gastric cancer","volume":"14","author":"Yu","year":"2021","journal-title":"Onco Targets Ther"},{"issue":"8","key":"10.1016\/j.blre.2023.101055_bb0525","doi-asserted-by":"crossref","first-page":"e320","DOI":"10.3324\/haematol.2016.143214","article-title":"Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia","volume":"101","author":"McGraw","year":"2016","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.blre.2023.101055_bb0530","doi-asserted-by":"crossref","first-page":"e345","DOI":"10.3324\/haematol.2018.205302","article-title":"TP53 immunohistochemistry correlates with TP53 mutation status and clearance in decitabine-treated patients with myeloid malignancies","volume":"104","author":"Ruzinova","year":"2019","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.blre.2023.101055_bb0535","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/his.14726","article-title":"Correlation of p53 immunohistochemistry with TP53 mutational status and overall survival in newly diagnosed acute myeloid leukaemia","volume":"81","author":"Fitzpatrick","year":"2022","journal-title":"Histopathology"},{"issue":"3","key":"10.1016\/j.blre.2023.101055_bb0540","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/modpathol.2016.206","article-title":"Immunohistochemistry for p53 is a useful tool to identify cases of acute myeloid leukemia with myelodysplasia-related changes that are TP53 mutated, have complex karyotype, and have poor prognosis","volume":"30","author":"Fernandez-Pol","year":"2017","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.blre.2023.101055_bb0545","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood.2021013983","article-title":"TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia","volume":"140","author":"Tashakori","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2023.101055_bb0550","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/cjp2.242","article-title":"Somatic intronic TP53 c.375+5G mutations are a recurrent but under-recognized mode of TP53 inactivation","volume":"8","author":"Chui","year":"2022","journal-title":"J Pathol Clin Res"},{"issue":"9","key":"10.1016\/j.blre.2023.101055_bb0555","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.3324\/haematol.2021.280487","article-title":"Pure erythroid leukemia is characterized by biallelic TP53 inactivation and abnormal p53 expression patterns in de novo and secondary cases","volume":"107","author":"Fang","year":"2022","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.blre.2023.101055_bb0560","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1038\/s41379-022-01062-2","article-title":"p53 null phenotype is a \"positive result\" in urothelial carcinoma in situ","volume":"35","author":"Sangoi","year":"2022","journal-title":"Mod Pathol"},{"issue":"5","key":"10.1016\/j.blre.2023.101055_bb0565","doi-asserted-by":"crossref","first-page":"459","DOI":"10.5468\/ogs.22102","article-title":"Clinical outcomes of immunohistochemistry of the p53 staining pattern in high-grade serous ovarian carcinoma","volume":"65","author":"Orachum","year":"2022","journal-title":"Obstet Gynecol Sci"},{"key":"10.1016\/j.blre.2023.101055_bb0570","article-title":"Reduced murine double minute 2 and 4 protein, but not messenger RNA, expression is associated with more severe disease in myelodysplastic syndromes and acute myeloblastic leukaemia","author":"Salomao","year":"2022","journal-title":"Br. J. Haematol."},{"issue":"18","key":"10.1016\/j.blre.2023.101055_bb0575","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.3390\/cancers14184519","article-title":"How I treat TP53-mutated acute myeloid leukemia and myelodysplastic syndromes","volume":"14","author":"Loschi","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.blre.2023.101055_bb0580","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2147\/OTT.S265637","article-title":"Targeting TP53-mutated acute myeloid leukemia: research and clinical developments","volume":"15","author":"Granowicz","year":"2022","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.blre.2023.101055_bb0585","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1200\/EDBK_199519","article-title":"Acute myeloid leukemia: the good, the bad, and the ugly","volume":"38","author":"Kuykendall","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"1","key":"10.1016\/j.blre.2023.101055_bb0590","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/leu.2008.173","article-title":"TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis","volume":"23","author":"Bowen","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2023.101055_bb0595","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1182\/blood-2018-99-117772","article-title":"TP53 mutations predict poorer responses to CPX-351 in acute myeloid leukemia","volume":"132","author":"Goldberg","year":"2018","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2023.101055_bb0600","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials","volume":"15","author":"Hills","year":"2014","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.blre.2023.101055_bb0605","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.blre.2023.101055_bb0610","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.3324\/haematol.2014.104760","article-title":"Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia","volume":"99","author":"Muller-Thomas","year":"2014","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.blre.2023.101055_bb0615","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1038\/s41375-018-0257-z","article-title":"Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care","volume":"32","author":"Dohner","year":"2018","journal-title":"Leukemia"},{"issue":"24","key":"10.1016\/j.blre.2023.101055_bb0620","doi-asserted-by":"crossref","first-page":"5272","DOI":"10.1158\/1078-0432.CCR-22-1183","article-title":"Outcomes in patients with poor-risk cytogenetics with or without TP53 mutations treated with venetoclax and azacitidine","volume":"28","author":"Pollyea","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.blre.2023.101055_bb0625","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1080\/10428194.2020.1864354","article-title":"Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of TP53 mutations - a registry based analysis","volume":"62","author":"Middeke","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"10.1016\/j.blre.2023.101055_bb0630","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1080\/10428194.2017.1422864","article-title":"Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia","volume":"59","author":"Boddu","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"10.1016\/j.blre.2023.101055_bb0635","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.blre.2023.101055_bb0640","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2023.101055_bb0645","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1111\/bjh.16166","article-title":"Venetoclax and hypomethylating agents in TP53-mutated acute myeloid leukaemia","volume":"187","author":"Aldoss","year":"2019","journal-title":"Br J Haematol"},{"issue":"20","key":"10.1016\/j.blre.2023.101055_bb0650","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1002\/cncr.33689","article-title":"Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax","volume":"127","author":"Kim","year":"2021","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.blre.2023.101055_bb0655","doi-asserted-by":"crossref","first-page":"e724","DOI":"10.1016\/S2352-3026(20)30210-6","article-title":"10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-Centre, phase 2 trial","volume":"7","author":"DiNardo","year":"2020","journal-title":"Lancet Haematol"},{"issue":"14","key":"10.1016\/j.blre.2023.101055_bb0660","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.20.02341","article-title":"Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes","volume":"39","author":"Sallman","year":"2021","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.blre.2023.101055_bb0665","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1200\/JCO.20.02342","article-title":"Eprenetapopt plus azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a phase II study by the Groupe Francophone des Myelodysplasies (GFM)","volume":"39","author":"Cluzeau","year":"2021","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.blre.2023.101055_bb0670","doi-asserted-by":"crossref","first-page":"7020","DOI":"10.1200\/JCO.2022.40.16_suppl.7020","article-title":"Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: phase 1b results","volume":"40","author":"Daver","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2023.101055_bb0675","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1182\/blood-2021-153638","article-title":"Phase I\/II study of azacitidine (AZA) with venetoclax (VEN) and magrolimab (Magro) in patients (pts) with newly diagnosed older\/unfit or high-risk acute myeloid leukemia (AML) and relapsed\/refractory (R\/R) AML","volume":"138","author":"Daver","year":"2021","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101055_bb0680","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1182\/blood-2021-146039","article-title":"Efficacy and safety of sabatolimab (MBG453) in combination with hypomethylating agents (HMAs) in patients (Pts) with very high\/high-risk myelodysplastic syndrome (vHR\/HR-MDS) and acute myeloid leukemia (AML): final analysis from a phase Ib study","volume":"138","author":"Brunner","year":"2021","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.blre.2023.101055_bb0685","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1182\/bloodadvances.2020002512","article-title":"TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML","volume":"4","author":"Vadakekolathu","year":"2020","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.blre.2023.101055_bb0690","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1182\/blood.2020007732","article-title":"Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia","volume":"137","author":"Uy","year":"2021","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.blre.2023.101055_bb0695","doi-asserted-by":"crossref","first-page":"14172","DOI":"10.18632\/oncotarget.7290","article-title":"Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents","volume":"7","author":"Takahashi","year":"2016","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.blre.2023.101055_bb0700","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/bjh.14455","article-title":"TP53 mutations predict decitabine-induced complete responses in patients with myelodysplastic syndromes","volume":"176","author":"Chang","year":"2017","journal-title":"Br J Haematol"},{"issue":"21","key":"10.1016\/j.blre.2023.101055_bb0705","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa1605949","article-title":"TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes","volume":"375","author":"Welch","year":"2016","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.blre.2023.101055_bb0710","doi-asserted-by":"crossref","first-page":"e756","DOI":"10.1016\/S2352-3026(22)00216-2","article-title":"Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1\u20132 study","volume":"9","author":"Bazinet","year":"2022","journal-title":"Lancet Haematol"},{"issue":"2","key":"10.1016\/j.blre.2023.101055_bb0715","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/ajh.26771","article-title":"A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes","volume":"98","author":"Zeidan","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2023.101055_bb0720","author":"therapeutics, A"},{"issue":"16_suppl","key":"10.1016\/j.blre.2023.101055_bb0725","doi-asserted-by":"crossref","first-page":"7017","DOI":"10.1200\/JCO.2022.40.16_suppl.7017","article-title":"Magrolimab in combination with azacitidine for untreated higher-risk myelodysplastic syndromes (HR-MDS): 5F9005 phase 1b study results","volume":"40","author":"Sallman","year":"2022","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101055_bb0730","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1182\/blood-2021-147962","article-title":"Phase II trial of eprenetapopt (APR-246) in combination with azacitidine (AZA) as maintenance therapy for TP53 mutated AML or MDS following allogeneic stem cell transplantation (SCT)","volume":"138","author":"Mishra","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101055_bb0735","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.59","article-title":"TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution","volume":"5","author":"Hou","year":"2015","journal-title":"Blood Cancer J"},{"issue":"26","key":"10.1016\/j.blre.2023.101055_bb0740","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.blre.2023.101055_bb0745","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","article-title":"Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission","volume":"383","author":"Wei","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.blre.2023.101055_bb0750","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1016\/j.blre.2023.101055_bb0755","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1158\/1078-0432.CCR-19-1900","article-title":"5-azacitidine induces NOXA to prime AML cells for venetoclax-mediated apoptosis","volume":"26","author":"Jin","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.blre.2023.101055_bb0760","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3109\/10428194.2014.910657","article-title":"Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies","volume":"56","author":"Bogenberger","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2023.101055_bb0765","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1182\/blood-2020-139492","article-title":"Safety, efficacy, and patient-reported outcomes of venetoclax in combination with azacitidine for the treatment of patients with higher-risk myelodysplastic syndrome: a phase 1b study","volume":"136","author":"Garcia","year":"2020","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2023.101055_bb0770","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1056\/NEJMoa1611604","article-title":"Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation","volume":"376","author":"Lindsley","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.blre.2023.101055_bb0775","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13045-017-0393-3","article-title":"Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)","volume":"10","author":"Poire","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"9","key":"10.1016\/j.blre.2023.101055_bb0780","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/ajh.25211","volume":"93","author":"Gilleece","year":"2018","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.blre.2023.101055_bb0785","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1182\/blood-2013-06-506725","article-title":"Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission","volume":"122","author":"Walter","year":"2013","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2023.101055_bb0790","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41408-021-00479-3","article-title":"Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT","volume":"11","author":"Gilleece","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2023.101055_bb0795","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1182\/blood-2019-131530","article-title":"Impact of TP53 gene mutation clearance and conditioning intensity on outcome in MDS or AML patients prior to allogeneic stem cell transplantation","volume":"134","author":"Chan","year":"2019","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.blre.2023.101055_bb0800","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1182\/bloodadvances.2019000388","article-title":"Allogeneic stem cell transplantation for high-risk acute leukemia and maintenance therapy: no time to waste","volume":"4","author":"Scott","year":"2020","journal-title":"Blood Adv"},{"issue":"26","key":"10.1016\/j.blre.2023.101055_bb0805","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.19.03345","article-title":"Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN)","volume":"38","author":"Burchert","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.blre.2023.101055_bb0810","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1182\/hematology.2022000325","article-title":"Novel investigational approaches for high-risk genetic subsets of AML: TP53, KMT2A, FLT3","volume":"2022","author":"Sahasrabudhe","year":"2022","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"5","key":"10.1016\/j.blre.2023.101055_bb0815","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ccr.2009.03.003","article-title":"PRIMA-1 reactivates mutant p53 by covalent binding to the core domain","volume":"15","author":"Lambert","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2023.101055_bb0820","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fonc.2016.00021","article-title":"Targeting of mutant p53 and the cellular redox balance by APR-246 as a strategy for efficient cancer therapy","volume":"6","author":"Bykov","year":"2016","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.blre.2023.101055_bb0825","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.3324\/haematol.2019.218453","article-title":"Synergistic effects of PRIMA-1(Met) (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia","volume":"105","author":"Maslah","year":"2020","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.blre.2023.101055_bb0830","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1093\/annonc\/mdz006","article-title":"The macrophage \u2018Do not eat me\u2019 signal, CD47, is a clinically validated cancer immunotherapy target","volume":"30","author":"Takimoto","year":"2019","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.blre.2023.101055_bb0835","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2020.101221","article-title":"The promise of macrophage directed checkpoint inhibitors in myeloid malignancies","volume":"33","author":"Swoboda","year":"2020","journal-title":"Best Pract Res Clin Haematol"},{"issue":"63","key":"10.1016\/j.blre.2023.101055_bb0840","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1126\/scitranslmed.3001375","article-title":"Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47","volume":"2","author":"Chao","year":"2010","journal-title":"Sci Transl Med"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101055_bb0845","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1182\/blood-2022-170188","article-title":"Phase I\/II study of azacitidine (AZA) with venetoclax (VEN) and magrolimab (Magro) in patients (pts) with newly diagnosed (ND) older\/unfit or high-risk acute myeloid leukemia (AML) and relapsed\/refractory (R\/R) AML","volume":"140","author":"Daver","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101055_bb0850","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.3389\/fonc.2019.01380","article-title":"Therapeutic targeting of the macrophage immune checkpoint CD47 in myeloid malignancies","volume":"9","author":"Chao","year":"2019","journal-title":"Front Oncol"},{"issue":"7","key":"10.1016\/j.blre.2023.101055_bb0855","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1111\/trf.15397","article-title":"The effects of monoclonal anti-CD47 on RBCs, compatibility testing, and transfusion requirements in refractory acute myeloid leukemia","volume":"59","author":"Brierley","year":"2019","journal-title":"Transfusion"},{"issue":"Supplement_1","key":"10.1016\/j.blre.2023.101055_bb0860","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1182\/blood-2019-126271","article-title":"The first-in-class anti-CD47 antibody magrolimab (5F9) in combination with azacitidine is effective in MDS and AML patients: ongoing phase 1b results","volume":"134","author":"Sallman","year":"2019","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2023.101055_bb0865","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1080\/14737140.2021.1865814","article-title":"TIM-3 pathway dysregulation and targeting in cancer","volume":"21","author":"Zeidan","year":"2021","journal-title":"Expert Rev Anticancer Ther"},{"issue":"3","key":"10.1016\/j.blre.2023.101055_bb0870","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41577-019-0224-6","article-title":"TIM3 comes of age as an inhibitory receptor","volume":"20","author":"Wolf","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.blre.2023.101055_bb0875","doi-asserted-by":"crossref","first-page":"4669","DOI":"10.1182\/blood-2021-145626","article-title":"Sabatolimab (MBG453) combination treatment regimens for patients (pts) with higher-risk myelodysplastic syndromes (HR-MDS): the MDS studies in the stimulus immuno-myeloid clinical trial program","volume":"138","author":"Zeidan","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2023.101055_bb0880","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1182\/blood-2014-05-575704","article-title":"Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform","volume":"127","author":"Al-Hussaini","year":"2016","journal-title":"Blood"},{"issue":"289","key":"10.1016\/j.blre.2023.101055_bb0885","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1126\/scitranslmed.aaa5693","article-title":"A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates","volume":"7","author":"Chichili","year":"2015","journal-title":"Sci Transl Med"},{"issue":"13","key":"10.1016\/j.blre.2023.101055_bb0890","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1182\/bloodadvances.2019030916","article-title":"Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed\/refractory acute myeloid leukemia","volume":"3","author":"Erba","year":"2019","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.blre.2023.101055_bb0895","doi-asserted-by":"crossref","DOI":"10.3390\/genes11060704","article-title":"Therapeutic editing of the TP53 gene: is CRISPR\/Cas9 an option?","volume":"11","author":"Mirgayazova","year":"2020","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.blre.2023.101055_bb0900","article-title":"CD47-SIRPalpha-targeted therapeutics: status and prospects","volume":"13","author":"Maute","year":"2022","journal-title":"Immunooncol Technol"},{"issue":"10","key":"10.1016\/j.blre.2023.101055_bb0905","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0164370","article-title":"Chromothripsis is a recurrent genomic abnormality in high-risk myelodysplastic syndromes","volume":"11","author":"Abaigar","year":"2016","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.blre.2023.101055_bb0910","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/nrc3352","article-title":"Chromothripsis and cancer: causes and consequences of chromosome shattering","volume":"12","author":"Forment","year":"2012","journal-title":"Nat Rev Cancer"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X23000164?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X23000164?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:31:02Z","timestamp":1759437062000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X23000164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":182,"alternative-id":["S0268960X23000164"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2023.101055","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TP53 in AML and MDS: The new (old) kid on the block","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2023.101055","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101055"}}